课题基金 / 基金详情

High throughput approach for generating human monoclonal antibodies

High throughput approach for generating human monoclonal antibodies
产生人单克隆抗体的高通量方法
批准号:
8904621
负责人:
Hiep T Tran
金额:
$22.48万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2017-06-30

项目摘要

项目成果

Hiep T Tran的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): Thanks to their exquisite specificity and sensitivity, monoclonal antibodies (Mab) have found a broad application in research, diagnosis and therapy. For treatment of human diseases, fully human antibodies are the most desirable as they are generally not immunogenic and well-tolerated. While there are several existing approaches for generation of antibodies, the processes are still time-consuming, labor-intensive, and unpredictable of success. To simplify and to accelerate the generation of fully human antibodies, a novel non-animal approach for antibody production is proposed. The objective will be achieved by using a Self-Diversifying Human Antibody Library (SHALib) effectively displayed on yeast cell surface. SHALib will provide a diverse array of antibodies in vitro, without the need of animal immunization and potential necessary humanization of the antibody. Starting from a naive antibody library from healthy human donors, antibodies with high-affinity and specificity to various targets will be generated and selected through repeated rounds of systematic evolution by somatic hypermutation, target-specific enrichment and fluorescence-activated cell sorting. Since this is a non-animal system, the platform can generate human antibodies against toxins, pathogens, self-antigens, and the like which are by nature difficult to obtain. As a proof-of-principle, in phase I, we will develop human antibodies to five selected targets of therapeutic importance. The targets are for the treatment of high cholesterol (PCSK9), rheumatoid arthritis (MMP1 and MMP13) and cancer (MMP7 and regulatory T cell protein CD25). In Phase II, the platform will be used to develop human monoclonal antibodies to at least 50 targets that are involved in different human diseases. The platform will allow generating quickly human monoclonal antibodies that are of therapeutic potential.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel immune-escape uricase for treatment of hyperuricemia
  • 批准号:
    10696609
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2023
  • 负责人:
    Hiep T Tran
  • 依托单位:
Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis
  • 批准号:
    10322911
  • 项目类别:
  • 资助金额:
    $39.91万
  • 财政年份:
    2021
  • 负责人:
    Hiep T Tran
  • 依托单位:
Development Of Arginine Linkage-Specific Antibodies
  • 批准号:
    9344737
  • 项目类别:
  • 资助金额:
    $22.49万
  • 财政年份:
    2017
  • 负责人:
    Hiep T Tran
  • 依托单位:
Modular antibody engineering to overcome the blood brain barrier
  • 批准号:
    9464412
  • 项目类别:
  • 资助金额:
    $23.66万
  • 财政年份:
    2017
  • 负责人:
    Hiep T Tran
  • 依托单位:
海外基金